Literature DB >> 8224221

The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide.

E M Lutz1, W J Sheward, K M West, J A Morrow, G Fink, A J Harmar.   

Abstract

We have cloned and sequenced a cDNA (RPR4) encoding a new member of the secretin/calcitonin/parathyroid hormone (PTH) receptor family. RPR4 was identified by PCR of rat pituitary cDNA, and a full-length clone was isolated from a rat olfactory bulb cDNA library. When RPR4 was functionally expressed in COS 7 cells, cyclic adenosine monophosphate (cAMP) production was stimulated by vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating peptides (PACAP-38 and PACAP-27) and helodermin, with equal potency. Peptide histidine isoleucine (PHI) and rat growth hormone releasing hormone (rGHRH) also stimulated cAMP production at lower potency. This suggests that RPR4 encodes a novel VIP receptor which we have designated the VIP2 receptor. In situ hybridisation showed that mRNA for this receptor was present mainly in the thalamus, hippocampus and in the suprachiasmatic nucleus.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8224221     DOI： 10.1016/0014-5793(93)81668-p

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  82 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor.

Authors:  J Hannibal; F Jamen; H S Nielsen; L Journot; P Brabet; J Fahrenkrug
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

3.  Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.

Authors:  E M Lutz; C J MacKenzie; M Johnson; K West; J A Morrow; A J Harmar; R Mitchell
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

Authors:  Amali E Samarasinghe; Scott A Hoselton; Jane M Schuh
Journal:  Peptides       Date:  2010-10-13       Impact factor: 3.750

Review 5.  Is bone a target-tissue for the nervous system? New advances on the understanding of their interactions.

Authors:  J M García-Castellano; P Díaz-Herrera; J A Morcuende
Journal:  Iowa Orthop J       Date:  2000

6.  Alternative splicing of the pituitary adenylate cyclase-activating polypetide (PACAP) receptor contributes to function of PACAP-27.

Authors:  Mina Ushiyama; Ryuji Ikeda; Morikatsu Yoshida; Kenji Mori; Kenji Kangawa; Hideki Sugawara; Kazuhiko Inoue; Katsushi Yamada; Atsuro Miyata
Journal:  J Mol Neurosci       Date:  2010-05-15       Impact factor: 3.444

Review 7.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 8.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 9.  Vasoactive intestinal peptide and the mammalian circadian system.

Authors:  Andrew M Vosko; Analyne Schroeder; Dawn H Loh; Christopher S Colwell
Journal:  Gen Comp Endocrinol       Date:  2007-05-26       Impact factor: 2.822

10.  Molecular cloning and characterization of two pig vasoactive intestinal polypeptide receptors (VPAC1-R and VPAC2-R).

Authors:  Xiaping He; Fengyan Meng; Yajun Wang; Juan Li
Journal:  DNA Cell Biol       Date:  2014-02-12       Impact factor: 3.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.